Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst

Keros Therapeutics, Inc. (NASDAQ:KROS) – HC Wainwright decreased their Q1 2026 earnings per share estimates for Keros Therapeutics in a report released on Thursday, March 5th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.89) for the quarter, down from their previous estimate of ($0.45). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.66) EPS, FY2027 earnings at ($7.14) EPS, FY2028 earnings at ($5.25) EPS and FY2029 earnings at ($3.90) EPS.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.37). The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $3.66 million. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.Keros Therapeutics’s quarterly revenue was down 87.2% on a year-over-year basis. During the same period in the prior year, the business earned ($1.14) EPS.

KROS has been the topic of several other reports. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 price objective (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Wall Street Zen downgraded shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Bank of America upped their price objective on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $21.86.

Keros Therapeutics Stock Down 3.5%

Shares of NASDAQ:KROS opened at $11.30 on Monday. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $22.55. The stock’s 50 day moving average is $17.41 and its 200-day moving average is $17.07. The firm has a market capitalization of $344.27 million, a price-to-earnings ratio of 6.21 and a beta of 0.87.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its stake in shares of Keros Therapeutics by 245.5% in the 2nd quarter. Franklin Resources Inc. now owns 132,301 shares of the company’s stock valued at $1,766,000 after purchasing an additional 94,006 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Keros Therapeutics by 154.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 257,518 shares of the company’s stock valued at $4,074,000 after purchasing an additional 156,221 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Keros Therapeutics by 107.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 265,707 shares of the company’s stock valued at $3,547,000 after purchasing an additional 137,604 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Keros Therapeutics during the 2nd quarter valued at $557,000. Finally, Western Standard LLC raised its holdings in Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after buying an additional 654,989 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

More Keros Therapeutics News

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: Leerink Partners initiated a Buy on Keros, providing third‑party validation that could support upside if clinical/commercial progress continues. Keros Therapeutics (KROS) Receives a Buy from Leerink Partners
• Positive Sentiment: Keros posted an updated investor presentation that highlights the rinfatercept strategy and commercialization plan — helpful for investors wanting clarity on timing, positioning and milestones for the lead program. Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
• Neutral Sentiment: Coverage pieces projecting long‑range outcomes (FY2030 estimates) were published; these sets of forecasts are informative but distant and less likely to move the stock by themselves unless they change near‑term guidance. Analysts Offer Predictions for KROS FY2030 Earnings
• Negative Sentiment: HC Wainwright cut multiple near‑term quarterly and multi‑year EPS forecasts (notable downward revisions for 2026–2029 and mixed adjustments to FY2026), signaling weaker anticipated profitability and increasing uncertainty around financial trajectory. HC Wainwright Cuts Estimates
• Negative Sentiment: Wall Street Zen lowered KROS to a Sell, adding downside pressure from the sell‑side and potentially prompting some holders to reduce exposure. Keros Therapeutics (NASDAQ:KROS) Lowered to Sell Rating by Wall Street Zen
• Negative Sentiment: Recent quarterly results showed a significant revenue miss and an EPS shortfall (reported March 4), which remain a material near‑term negative underpinning analysts’ downward estimate revisions and investor caution. KROS Recent Earnings Report

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.